These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1286560)

  • 1. Leukocyte-reduced blood components in transfusion medicine. Current indications and prospects for the future.
    Klapper EB; Goldfinger D
    Clin Lab Med; 1992 Dec; 12(4):711-21. PubMed ID: 1286560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of leukocyte-reduced blood components.
    Miller JP; Mintz PD
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):69-90. PubMed ID: 7737945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force.
    Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462
    [No Abstract]   [Full Text] [Related]  

  • 4. From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes.
    Lee JH; Klein HG
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):585-600. PubMed ID: 11102278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection.
    Rawal BD; Davis RE; Busch MP; Vyas GN
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):36-41. PubMed ID: 2134639
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in transfusion therapy.
    Beck SJ
    Clin Lab Sci; 1994; 7(4):225-31. PubMed ID: 10147432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effects of transfusions caused by leukocytes.
    Raife TJ
    J Intraven Nurs; 1997; 20(5):238-44. PubMed ID: 9369624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte depletion of cellular blood components.
    Lane TA
    Curr Opin Hematol; 1994 Nov; 1(6):443-51. PubMed ID: 9371321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion medicine 1994.
    Pineda A; Korbling M; Rock GA
    Rev Invest Clin; 1994 Apr; Suppl():101-15. PubMed ID: 7886293
    [No Abstract]   [Full Text] [Related]  

  • 11. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
    Corash L
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transfusion of blood and blood derivatives. Measurements of safety, circulatory, immunologic and infectious risks and accidents].
    Rouger P; Hergon E
    Rev Prat; 1997 Sep; 47(13):1499-504. PubMed ID: 9339033
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical issues in neonatal transfusion practice.
    Strauss RG
    Am J Clin Pathol; 1997 Apr; 107(4 Suppl 1):S57-63. PubMed ID: 9124231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Present status and future of blood management in Japan].
    Sekiguchi S; Ikebuchi K
    Nihon Naika Gakkai Zasshi; 1996 Jun; 85(6):862-70. PubMed ID: 8753053
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs.
    Lane TA
    Arch Pathol Lab Med; 1994 Apr; 118(4):392-404. PubMed ID: 8166589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Why remove leukocytes from labile blood products in 1995?].
    Andreu G; Belhocine R; Klaren J; Fretz C; Lejus C
    Transfus Clin Biol; 1996; 3(1):57-74. PubMed ID: 8640315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease.
    Corash L; Lin L
    Bone Marrow Transplant; 2004 Jan; 33(1):1-7. PubMed ID: 14647263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic effects of leukocytes present in transfused cellular blood products.
    Bordin JO; Heddle NM; Blajchman MA
    Blood; 1994 Sep; 84(6):1703-21. PubMed ID: 8080981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Importance and indications for leukocyte-free blood products].
    Jullien AM
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):211-3. PubMed ID: 8337129
    [No Abstract]   [Full Text] [Related]  

  • 20. Transfusion-transmitted infections.
    Bihl F; Castelli D; Marincola F; Dodd RY; Brander C
    J Transl Med; 2007 Jun; 5():25. PubMed ID: 17553144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.